Literature DB >> 35351413

Endometriosis promotes atherosclerosis in a murine model.

Ramanaiah Mamillapalli1, Nikoletta Toffoloni2, Shutaro Habata2, Huang Qunhua3, Rula Atwani2, Nina Stachenfeld2, Hugh S Taylor4.   

Abstract

BACKGROUND: Epidemiologic studies have demonstrated an association between endometriosis and the subsequent development of cardiovascular disease. The direct effect of endometriosis on the progression of atherosclerotic, if any, has not been previously characterized. Endometriosis leads to systemic inflammation that could have consequences for cardiovascular health. Here, we reported the effects of endometriosis on the development of atherosclerosis in a murine model.
OBJECTIVE: This study aimed to determine the contribution of endometriosis in promoting cardiovascular disease in a murine model of endometriosis. STUDY
DESIGN: Endometriosis was induced in 18 apolipoprotein E-null mice, the standard murine model used to study atherosclerosis. Mice of the same strain were used as controls (n=18) and underwent sham surgery without inducing endometriosis. The formation of endometriotic lesions was confirmed after 25 weeks of induction. Atherosclerotic lesions were subjected to hematoxylin and eosin staining followed by measurement of the aortic root luminal area and wall thickness. The whole aorta was isolated, and Oil Red O staining was performed to quantify the lipid deposits or plaque formation; moreover, biochemical assays were carried out in serum to determine the levels of lipids and inflammatory-related cytokines.
RESULTS: Apolipoprotein E mice with endometriosis exhibited increased aortic atherosclerosis compared with controls as measured using Oil Red O staining (7.9% vs 3.1%, respectively; P=.0004). Mice with endometriosis showed a significant 50% decrease in the aortic luminal area compared with sham mice (0.85 mm2 vs 1.46 mm2; P=.03) and a significant increase in aortic root wall thickness (0.22 mm vs 0.15 mm; P=.04). There was no difference in the lipoprotein profile (P<.05) between mice with endometriosis and sham mice. The serum levels of inflammatory cytokines interleukin 1 alpha, interleukin 6, interferon gamma, and vascular endothelial growth factor were significantly (P<.05)increased in the endometriosis mice.
CONCLUSION: Our study used a murine model to determine the effect of endometriosis on atherosclerosis. Inflammation-related cytokines interleukin 1 alpha, interleukin 6, interferon gamma, and vascular endothelial growth factor (angiogenic factor) released by endometriotic lesions may contribute to the increased cardiovascular risks in women with endometriosis. To reduce the risk of cardiovascular disease, early identification and treatment of endometriosis are essential. Future treatments targeting inflammatory cytokines may help reduce the long-term risk of cardiovascular disease in women with endometriosis.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  apolipoprotein E mice; atherosclerosis; cardiovascular disease; cytokines; endometriosis; inflammation; plaques

Mesh:

Substances:

Year:  2022        PMID: 35351413      PMCID: PMC9308711          DOI: 10.1016/j.ajog.2022.03.040

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   10.693


  66 in total

Review 1.  Atherosclerosis. the road ahead.

Authors:  C K Glass; J L Witztum
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

Review 2.  Endometriosis.

Authors:  Serdar E Bulun
Journal:  N Engl J Med       Date:  2009-01-15       Impact factor: 91.245

Review 3.  The Systemic Effects of Endometriosis.

Authors:  Myles H Alderman; Nicole Yoder; Hugh S Taylor
Journal:  Semin Reprod Med       Date:  2017-06-28       Impact factor: 1.303

4.  Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction.

Authors:  P M Ridker; N Rifai; M Pfeffer; F Sacks; S Lepage; E Braunwald
Journal:  Circulation       Date:  2000-05-09       Impact factor: 29.690

5.  Link between Endometriosis, Atherosclerotic Cardiovascular Disease, and the Health of Women Midlife.

Authors:  Omur Taskin; Kiran Rikhraj; Justin Tan; Tara Sedlak; Timothy C Rowe; Mohamed A Bedaiwy
Journal:  J Minim Invasive Gynecol       Date:  2019-04-25       Impact factor: 4.137

6.  Role of endometriosis in defining cardiovascular risk: a gender medicine approach for women's health.

Authors:  Michela Cirillo; Maria Elisabetta Coccia; Felice Petraglia; Cinzia Fatini
Journal:  Hum Fertil (Camb)       Date:  2021-04-30       Impact factor: 2.767

7.  ESHRE guideline for the diagnosis and treatment of endometriosis.

Authors:  Stephen Kennedy; Agneta Bergqvist; Charles Chapron; Thomas D'Hooghe; Gerard Dunselman; Robert Greb; Lone Hummelshoj; Andrew Prentice; Ertan Saridogan
Journal:  Hum Reprod       Date:  2005-06-24       Impact factor: 6.918

8.  Correction: Pathophysiology of Endometriosis: Role of High Mobility Group Box-1 and Toll-Like Receptor 4 Developing Inflammation in Endometrium.

Authors:  Bo Hyon Yun; Seung Joo Chon; Young Sik Choi; SiHyun Cho; Byung Seok Lee; Seok Kyo Seo
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

9.  Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression.

Authors:  Alexander M Kotlyar; Ramanaiah Mamillapalli; Valerie A Flores; Hugh S Taylor
Journal:  Mol Hum Reprod       Date:  2021-03-24       Impact factor: 4.025

10.  CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking.

Authors:  Nicola Pluchino; Ramanaiah Mamillapalli; Shafiq Shaikh; Shutaro Habata; Aya Tal; Marie Gaye; Hugh S Taylor
Journal:  J Cell Mol Med       Date:  2020-01-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.